EVQLV Joins Endless Frontier Labs Incubator

Sep 21, 2020 | News | 0 comments

EVQLV

NEW YORK, September 21, 2020 — EVQLV has been invited to join the Life Science Track of the prestigious Endless Frontier Labs (EFL) incubator. The nine-month program runs each year from October through May. The program provides:

  • Guidance from industry executives to help entrepreneurs land strategic partnerships, gain regulatory approval, and/or acquire customers

  • Scientific and operational mentorships with leaders who have taken companies through successful exits to provide companies with advice regarding high-level business development and R&D strategy

  • Input from vertical-specific investors who give critical advice from a “smart money” perspective

About Endless Frontier Labs

Founded at NYU Stern School of Business and located in New York City, Endless Frontier Labs (EFL) is at the intersection of world-renowned research and the most dynamic and innovative city in the world. EFL is a structured mentoring program that provides founders with resources, support and advice to optimize their chances for success. According to EFL’s founding director, Professor Deepak Hegde, “Our mission is to bridge the gap between science and societal impact. We believe business strategy, validation by scientific peers, and connections to investors are essential for the successful commercialization of scientific breakthroughs. To that end, EFL provides founders access to an unparalleled network of business coaches, scientists, investors, and Stern MBA students to help transform their ideas into high-growth businesses.”

0 Comments

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...

Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo

NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...

EVQLV Accepted to Prestigious Techstars Boston Accelerator

NEW YORK, November 18, 2020 -- EVQLV, a New York company that uses AI to accelerate the development of antibodies, will be one of 10 startups in the new class of the Techstars Boston program. This year’s program will be 100% virtual and, for the first time, will...

Pin It on Pinterest